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Incessant ventricular tachyarrhythmia (including ventricular
brillation, polymorphic and monomorphic ventricular tachycar-
ia), which can be a cause of sudden cardiac death, occurs in
atients with various cardiac and non-cardiac diseases. Such an
rrhythmia may  also happen in healthy subjects and is called “idio-
athic ventricular tachyarrhythmia”. To rescue patients from these
ife-threatening ventricular tachyarrhythmias, initial management
s essential. However, appropriate therapy is not identical in each
ause (or background) of ventricular tachyarrhythmia. Of course,
or termination of ventricular ﬁbrillation or hemodynamically
nstable ventricular tachycardia, deﬁbrillation (or cardioversion)
hock is the only reliable therapy to restore sinus rhythm. However,
he same ventricular tachyarrhythmia may  recur within a short
eriod repetitively unless the underlying arrhythmogenic causes
re successfully treated.
For the suppression of incessant episodes of ventricular tach-
arrhythmia in patients with impaired cardiac function due to
tructural heart diseases, treatment combining beta-blockers, deep
edation, and/or intravenous administration of amiodarone (or
ifekalant) would be chosen [1].  Twelve-lead electrocardiogram
ECG), echocardiogram, chest X-ray, and/or serological test includ-
ng the measurement of brain natriuretic peptide, etc., are all useful
n estimating the magnitude of the cardiac dysfunction and to
dentify the underlying heart disease(s). Repetitive form of ventri-
ular tachyarrhythmias can also develop during acute myocardial
schemia. In such situations, coronary revascularization may  be the
rimary therapy in suppressing the ventricular tachyarrhythmias.
Therapeutic approaches for ventricular tachyarrhythmias in
atients without structural heart diseases are different from those
n patients with structural heart disease. For example, intravenous
soproterenol infusion would be the ﬁrst treatment for repeti-
ive arrhythmic events in patients with Brugada syndrome or in
atients with J-wave associated idiopathic ventricular ﬁbrillation
2]. Twelve-lead ECG is an important clue (coved-type ST-segment
levation in V1–V3 leads for Brugada syndrome and slurred or
otched J wave in inferior and/or lateral leads in J-wave syn-
rome) to reach a correct diagnosis of these syndromes. Similarly,
DOI of original article: http://dx.doi.org/10.1016/j.jccase.2012.06.012.
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ttp://dx.doi.org/10.1016/j.jccase.2012.09.001abnormal QT interval prolongation on 12-lead ECG is important to
reach a diagnosis of congenital (or acquired) long QT  syndrome
(LQTS). Magnesium infusion, faster-pacing and/or supplemental
treatment with potassium would be chosen in suppressing recur-
rent episodes of polymorphic ventricular tachycardia in LQTS
patients [2].
As a case presented in this journal [3],  drug toxicity and/or elec-
trolyte disturbance is another important cause of repetitive attacks
of ventricular tachyarrhythmia. However, in the emergency room,
reaching a diagnosis of these conditions may not always be easy,
especially in patients ﬁrst arriving by ambulance.
Arrhythmias induced by digitalis toxicity or hyperkalemia
In the article by Mori et al. [3],  the patient showed repetitive
episodes of polymorphic ventricular tachycardia and accelerated
idioventricular rhythm. Basic beats, which were recorded between
the intervals of the repetitive ventricular arrhythmias, showed a
widening QRS complex and normal QT interval suggesting slowed
ventricular conduction and non-prolonged ventricular repolariza-
tion, respectively.
It is well known that many arrhythmias (including paroxysmal
atrial tachycardia with block, various degrees of atrio-ventricular
block, premature ventricular tachycardia, accelerated idioventric-
ular rhythm, etc.) can be induced by digitalis toxicity. Although
characteristically tall T wave is considered an initial sign of hyper-
kalemia, PR interval prolongation, ﬂattening of P wave, widening of
QRS complex, and/or development of life-threatening ventricular
tachyarrhythmia would emerge on the ECG as the stage of hyper-
kalemia progressed. Therefore, from only the ECGs in the patient
reported by Mori et al., it might be difﬁcult to obtain an immedi-
ate diagnosis of digitalis toxicity combined with hyperkalemia as a
cause of the repetitive episodes of ventricular tachyarrhythmias.
Therapeutic approach for ventricular tachyarrhythmias
associated with digitalis toxicity and hyperkalemia
Although the authors used lidocaine as the ﬁrst treatment,
intravenous administration of lidocaine is not indicated for
the treatment of ventricular arrhythmias associated with digi-
talis toxicity [4].  However, at emergency admission, therapeutic
intervention for malignant ventricular arrhythmias may  need
to be started before obtaining complete laboratory results. As
an appropriate treatment for digitalis toxicity, the American
Heart Association/American College of Cardiology guideline (2006)
vier Ltd. All rights reserved.
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ecommends the following [4].  Among these options, an antidigi-
alis antibody is unavailable in Japan.
lass I
An antidigitalis antibody is recommended for patients who
resent with sustained ventricular arrhythmias, advanced atrio-
entricular block, and/or asystole that are considered due to
igitalis toxicity. (Level of Evidence: A)
lass IIa
. Patients taking digitalis who present with mild cardiac toxic-
ity (e.g. isolated ectopic beats only) can be managed effectively
with recognition, continuous monitoring of cardiac rhythm,
withdrawal of digitalis, restoration of normal electrolyte levels
(including serum potassium greater than 4 mM/L), and oxygen-
ation. (Level of Evidence: C)
. Magnesium or pacing is reasonable for patients who take dig-
italis and present with severe toxicity (sustained ventricular
arrhythmias, advanced atrio-ventricular block, and/or asystole).
(Level of Evidence: C)
lass IIb
Dialysis for the management of hyperkalemia may  be consid-
red for patients who take digitalis and present with severe toxicity
sustained ventricular arrhythmias; advanced atrio-ventricular
lock, and/or asystole). (Level of Evidence: C)
lass III
Management by lidocaine or phenytoin is not recommended for
atients taking digitalis and who present with severe toxicity (sus-
ained ventricular arrhythmias, advanced atrio-ventricular block,
nd/or asystole). (Level of Evidence: C)
As a treatment for hyperkalemia, emergent interventions are
sually recommended either when any ﬁndings indicating hyper-
alemia are recorded on ECG or serum potassium level is elevated
o more than 6.0 mEq/L. Calcium gluconate hydrate, glucose ﬂuid
lus insulin, sodium bicarbonate, calcium polystyrene sulfate,
nd/or furosemide are considered to be effective in lowering the
erum level of potassium, but hemodialysis may  be required in
erious cases (including patients with renal insufﬁciency). The
atient reported by Mori et al. showed life-threatening ventricu-
ar tachyarrhythmias, thus she required emergent treatment for
yperkalemia (8.3 mEq/L). Indeed, the authors successfully treated
he hyperkalemia by use of the combined treatment of glucose ﬂuid
lus insulin, sodium bicarbonate, and calcium polystyrene sulfate.
ollowing the treatment of the hyperkalemia and digitalis toxicity,
he incessant form of ventricular tachyarrhythmias spontaneously
isappeared.
In the patient reported by Mori et al. [3],  dehydration, which was
aused by vomiting and anorexia 2 days before the admission, was
he most likely trigger of the digitalis toxicity and hyperkalemia.
lthough laboratory tests before the arrhythmic event did not indi-
ate severe renal dysfunction (serum creatinine was  0.76 mg/dL
nd estimated glomerular ﬁltration rate was 56.1 mL/min/1.73 m2),
er renal dysfunction was advanced at the time of the arrhyth-
ic  event (serum creatinine was elevated to 1.57 mg/dL). Since this
atient was a 74-year-old and had been treated by insulin for type 2
iabetes mellitus, it is highly possible that the patient had suffered
rom clinically un-manifested renal dysfunction.ases 6 (2012) e185–e186
In elderly patients suffering from cardiac diseases and/or dia-
betes mellitus, renal function may  easily be altered by various
factors. Physicians need to be aware of the possibility of poten-
tial renal dysfunction especially when drugs, which are primarily
metabolized in the kidneys, are prescribed in such patients.
Hypertrophic cardiomyopathy could have worked as an
arrhythmogenic substrate of the ventricular tachyarrhythmias in
the patient reported by Mori et al. Since cardiac magnetic resonance
imaging of this patient revealed a thick myocardium surround-
ing the entire left ventricle and a relatively preserved ventricular
contraction, diastolic (rather than systolic) dysfunction of the left
ventricle and presence of atrial ﬁbrillation would seem to be a likely
cause of her history of heart failure. Although a detailed clinical
course of this patient was  uncertain, beta-blocker or calcium antag-
onist might be suitable for the rate control of atrial ﬁbrillation in
this patient.
Summary
For the emergency treatment of incessant ventricular tach-
yarrhythmias, cardiologists and physicians should make their best
effort to clarify the underlying mechanism of ventricular tach-
yarrhythmia so as to immediately apply the most appropriate
treatment in order to save the life of their patients.
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